GO:0004714 transmembrane receptor protein tyrosine kinase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0004714 describes the molecular function of transmembrane receptors that bind an extracellular signal and transmit it across the membrane by phosphorylating protein tyrosine residues using ATP.
• Receptor tyrosine kinases (RTKs) share a conserved architecture: an extracellular ligand-binding domain, a single transmembrane helix, and a cytoplasmic tyrosine kinase domain.
• Ligand-induced dimerization or oligomerization is the canonical activation mechanism that relieves autoinhibition and enables trans-autophosphorylation.
• RTK signaling controls proliferation, differentiation, survival, and metabolism, and its dysregulation is central to many cancers and metabolic disorders.
• Key RTK families include ErbB/HER, FGFR, insulin receptor, and KIT, each with distinct ligands and downstream pathways.
• CRISPR-based knockout, point-mutation, knock-in, and overexpression models enable causal dissection of RTK function in disease and drug response.
Description
Transmembrane receptor protein tyrosine kinase activity (GO:0004714) is a molecular function that combines signal binding with signal transduction across a biological membrane. The receptor binds an extracellular ligand and, upon activation, catalyzes the transfer of the gamma-phosphate of ATP to tyrosine residues on protein substrates, thereby initiating intracellular signaling cascades. This activity is encoded by receptor tyrosine kinases (RTKs), a large family of cell-surface receptors that includes the ErbB/HER, FGFR, insulin receptor, and KIT families. Because RTKs sit at the interface between the extracellular environment and intracellular signaling networks, they are critical for normal development and tissue homeostasis, and their dysfunction is a major driver of human disease. Researchers study GO:0004714 to understand how extracellular cues are converted into cellular responses such as proliferation, survival, migration, and differentiation. The catalytic mechanism, regulatory autoinhibition, and ligand-induced activation of RTKs have been extensively characterized. Dysregulated RTK activity, often through mutation, amplification, or autocrine ligand production, is a hallmark of many cancers and is also implicated in metabolic and developmental disorders. Consequently, RTKs are among the most successful targets for small-molecule inhibitors and therapeutic antibodies. This article provides a research-grade overview of GO:0004714, covering its definition, biological and molecular mechanisms, key genes, disease relevance, and experimental models including CRISPR-based approaches. All statements are grounded in the verified literature cited by number.
transmembrane receptor protein tyrosine kinase activity At A Glance
| GO ID | GO:0004714 |
|---|---|
| GO term | transmembrane receptor protein tyrosine kinase activity |
| Ontology | molecular_function |
| Synonym | receptor protein tyrosine kinase activity; receptor protein-tyrosine kinase activity |
| Definition | Combining with a signal and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity by catalysis of the reaction: ATP + a protein-L-tyrosine = ADP + a protein-L-tyrosine phosphate. |
| Major function | Ligand-activated tyrosine phosphorylation of protein substrates, initiating intracellular signaling cascades. |
| Cellular location | Plasma membrane; single-pass transmembrane receptors with extracellular ligand-binding domain and cytoplasmic kinase domain. |
| Representative genes | EGFR, ERBB2, FGFR1, INSR, KIT, and other receptor tyrosine kinases. |
| Reaction | ATP + protein-L-tyrosine = ADP + protein-L-tyrosine phosphate. |
What Is GO:0004714?
GO:0004714, transmembrane receptor protein tyrosine kinase activity, is defined as combining with a signal and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity by catalysis of the reaction: ATP + a protein-L-tyrosine = ADP + a protein-L-tyrosine phosphate. In other words, it is the enzymatic activity of a membrane-spanning receptor that, upon binding an extracellular ligand, phosphorylates tyrosine residues on target proteins using ATP as the phosphate donor. This activity couples ligand recognition to intracellular signaling and is a hallmark of receptor tyrosine kinases.
Why Is transmembrane receptor protein tyrosine kinase activity Important in Cell Biology?
GO:0004714 is fundamental to how cells sense and respond to their environment. Receptor tyrosine kinases mediate signaling by growth factors, hormones, and cytokines, controlling processes such as cell proliferation, survival, differentiation, and metabolism. Dysregulation of these kinases through mutation, overexpression, or autocrine loops drives many human cancers and contributes to metabolic and developmental disorders. Because of their central role, RTKs are major targets for therapeutic intervention, and understanding their activity is essential for drug discovery and precision medicine.
• RTK activity is essential for embryonic development and tissue homeostasis.
• Mutations and amplifications in RTKs such as EGFR, ERBB2, FGFR1, and KIT are oncogenic drivers in multiple cancers.
• RTKs are the targets of approved small-molecule inhibitors and therapeutic antibodies, making GO:0004714 a key function in cancer pharmacology.
• Insulin receptor tyrosine kinase activity is critical for glucose homeostasis and metabolic regulation.
• Ligand-induced activation mechanisms inform the design of biologics and receptor antagonists.
• RTK signaling intersects with major pathways including MAPK, PI3K-AKT, and JAK-STAT, influencing diverse cellular outcomes.
• Understanding RTK autoinhibition and activation is key to overcoming drug resistance.
• CRISPR screens targeting RTK genes can identify vulnerabilities and resistance mechanisms.
Mechanism, Genes and Research Methods
Ligand Binding and Receptor Dimerization
In simple terms: A growth factor binds to the outside of the receptor, causing two receptors to pair up.
The first step in transmembrane receptor protein tyrosine kinase activity is the binding of an extracellular ligand to the receptor's ectodomain. This binding induces conformational changes that promote receptor dimerization or oligomerization, bringing two kinase domains into close proximity. For example, ErbB/HER receptors undergo ligand-induced dimerization, which is a prerequisite for kinase activation. The dimerization interface and ligand specificity vary among RTK families, but the general principle of ligand-induced clustering is conserved.
Kinase Domain Activation and Autophosphorylation
In simple terms: Once paired, the intracellular kinase domains activate each other by adding phosphate groups.
Dimerization relieves autoinhibitory interactions in the cytoplasmic kinase domain, allowing the two kinase domains to trans-autophosphorylate tyrosine residues in their activation loops. This autophosphorylation stabilizes the active conformation and creates docking sites for downstream signaling proteins containing SH2 or PTB domains. The catalytic mechanism involves ATP binding, transfer of the gamma-phosphate to tyrosine, and release of ADP. Structural studies have elucidated the conserved kinase fold and the regulatory roles of the activation loop and juxtamembrane region.
Downstream Signaling and Cellular Responses
In simple terms: The phosphorylated receptor recruits and activates proteins that relay the signal inside the cell.
Phosphotyrosine residues on the activated receptor serve as docking sites for adaptor and effector proteins, leading to activation of canonical pathways such as RAS-MAPK, PI3K-AKT, and JAK-STAT. These pathways drive changes in gene expression, metabolism, cytoskeletal dynamics, and cell fate. The specificity of downstream signaling is determined by the complement of phosphotyrosine sites and the cellular context. Dysregulation of these events can lead to uncontrolled proliferation and survival.
Negative Regulation and Signal Attenuation
In simple terms: Cells have brakes to turn off the receptor signal after it has done its job.
RTK activity is tightly regulated by negative feedback mechanisms, including receptor internalization, degradation, and dephosphorylation by protein tyrosine phosphatases. For instance, transmembrane protein tyrosine phosphatases can dephosphorylate RTKs and modulate signaling duration and intensity. Additionally, ligand-induced downregulation and ubiquitin-mediated degradation control the strength and duration of signaling. Loss of these regulatory mechanisms can contribute to oncogenesis.
Key Genes Involved in GO:0004714 transmembrane receptor protein tyrosine kinase activity
The following genes encode representative transmembrane receptor protein tyrosine kinases and related proteins, with their major roles and research relevance.
| Gene | Major Role | Research Relevance |
|---|---|---|
| EGFR | ErbB family RTK; binds EGF; drives proliferation and survival | Mutated/amplified in lung, breast, and other cancers; target of inhibitors. |
| ERBB2 (HER2) | ErbB family RTK; heterodimerizes with other ErbB members | Amplified in breast and gastric cancers; target of trastuzumab. |
| ERBB3 | ErbB family RTK; kinase-impaired but signaling-competent partner | Implicated in cancer and drug resistance. |
| ERBB4 | ErbB family RTK; binds neuregulins | Roles in development and cancer. |
| FGFR1 | FGF receptor; regulates proliferation and differentiation | Amplified/mutated in cancers; target of FGFR inhibitors. |
| FGFR2 | FGF receptor; involved in development and tissue repair | Mutations in cancers and skeletal disorders. |
| FGFR3 | FGF receptor; regulates bone growth | Mutations in bladder cancer and achondroplasia. |
| INSR | Insulin receptor; mediates metabolic signaling | Key for diabetes and metabolic research. |
| IGF1R | IGF-1 receptor; promotes growth and survival | Target in cancer and growth disorders. |
| KIT | Stem cell factor receptor; regulates hematopoiesis and pigmentation | Mutations in GIST and mastocytosis; target of imatinib. |
| PDGFRA | PDGF receptor alpha; regulates mesenchymal cells | Mutations in GIST and other cancers. |
| VEGFR2 (KDR) | VEGF receptor; drives angiogenesis | Target of anti-angiogenic therapies. |
| MET | HGF receptor; regulates motility and survival | Amplified/mutated in lung and other cancers. |
| ALK | Anaplastic lymphoma kinase; neuronal development | Fusions in lymphoma and lung cancer; target of inhibitors. |
| RET | GDNF receptor; neural crest development | Mutations in thyroid cancer and MEN2. |
| NTRK1 (TRKA) | NGF receptor; pain and neuronal survival | Fusions in various cancers; target of TRK inhibitors. |
| PTPRJ | Receptor protein tyrosine phosphatase; negative regulator | Modulates RTK signaling; tumor suppressor candidate. |
How Is transmembrane receptor protein tyrosine kinase activity Regulated?
Transmembrane receptor protein tyrosine kinase activity is regulated at multiple levels. Ligand availability and affinity control the initial activation step. Receptor dimerization and conformational changes relieve autoinhibition, while autophosphorylation stabilizes the active state. Negative regulation is mediated by protein tyrosine phosphatases, such as receptor-type PTPs, which dephosphorylate RTKs and attenuate signaling. Additionally, endocytosis and ubiquitin-mediated degradation remove activated receptors from the cell surface, and feedback phosphorylation by downstream kinases can desensitize the receptor. These layers of regulation ensure appropriate signal duration and prevent aberrant activation.
transmembrane receptor protein tyrosine kinase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| EGFR | Non-small cell lung cancer; glioblastoma | Point-mutation knock-in of L858R or exon 19 deletion in cell lines; KO for dependency studies. |
| ERBB2 | Breast and gastric cancer | Overexpression and amplification models; knock-in of activating mutations. |
| FGFR3 | Achondroplasia; bladder cancer | Point-mutation knock-in of G380R; KO to study bone growth. |
| KIT | Gastrointestinal stromal tumor; mastocytosis | Knock-in of D816V; KO for hematopoiesis studies. |
| INSR | Diabetes and insulin resistance | KO and point-mutation models to dissect kinase activity in metabolic tissues. |
Cancer
Dysregulated RTK activity is a hallmark of many cancers. Activating mutations, gene amplifications, and chromosomal rearrangements in RTKs such as EGFR, ERBB2, FGFR1, KIT, and ALK drive tumor growth and survival. For example, EGFR mutations are common in non-small cell lung cancer, and ERBB2 amplification occurs in breast and gastric cancers. FGFR alterations are found in multiple tumor types, and KIT mutations are characteristic of gastrointestinal stromal tumors. Targeting these kinases with small-molecule inhibitors or antibodies has proven clinically effective, but resistance often emerges, necessitating combination therapies and new inhibitors.
Metabolic Disorders
The insulin receptor (INSR) is a transmembrane receptor tyrosine kinase critical for glucose uptake and metabolism. Defects in INSR signaling contribute to insulin resistance and diabetes. Research into INSR kinase activity informs the development of insulin analogs and small-molecule activators. Other RTKs, such as FGFR1, also influence metabolic homeostasis, and their dysregulation can affect energy balance.
Developmental and Skeletal Disorders
RTK signaling is essential for normal development. Mutations in FGFR2 and FGFR3 cause craniosynostosis syndromes and achondroplasia, respectively, due to altered kinase activity. KIT mutations affect hematopoiesis and pigmentation, leading to disorders such as piebaldism. These examples highlight the importance of precise RTK regulation in tissue patterning and organogenesis.
From transmembrane receptor protein tyrosine kinase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of RTK function affect cell proliferation? | CRISPR knockout of the RTK gene in cancer cell lines. |
| How does a specific kinase-domain mutation alter signaling? | Point-mutation knock-in of the mutation (e.g., EGFR L858R). |
| Can a fusion protein drive oncogenesis? | Knock-in of chromosomal rearrangement (e.g., EML4-ALK). |
| Where is the receptor localized and trafficked? | Tagged knock-in with fluorescent or epitope tag. |
| Does overexpression mimic amplification in cancer? | Overexpression of wild-type or mutant RTK. |
| Which genes mediate resistance to RTK inhibitors? | Genome-wide CRISPR library screening. |
How to Study the transmembrane receptor protein tyrosine kinase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout | Loss of RTK protein and function | Determining dependency and signaling roles. |
| Phospho-tyrosine Western blot | Receptor autophosphorylation and downstream phosphorylation | Validating activation status and inhibitor effects. |
| Phosphoproteomics | Global tyrosine phosphorylation changes | Mapping signaling networks downstream of RTKs. |
| X-ray crystallography | Three-dimensional structure of kinase or ectodomain | Understanding activation mechanisms and drug binding. |
| CRISPR library screen | Genes required for growth or drug resistance | Identifying synthetic lethal partners. |
| Conditional knock-in mouse | Physiological consequences of specific mutations | Modeling human disease and testing therapies. |
| Surface plasmon resonance | Ligand-receptor binding affinity | Characterizing ligand specificity. |
| Immunofluorescence | Subcellular localization of receptors | Studying trafficking and internalization. |
CRISPR-Cas9 Knockout
CRISPR-Cas9 knockout is widely used to ablate RTK genes and assess loss-of-function phenotypes. This approach can reveal whether a specific RTK is required for proliferation, survival, or signaling in a given cell type. Knockout cell pools or clones can be validated by sequencing and immunoblotting, and then subjected to downstream assays such as phospho-proteomics or viability screens.
Phosphoproteomics and Western Blotting
Phosphoproteomic profiling using mass spectrometry can globally map tyrosine phosphorylation events downstream of RTK activation. Western blotting with phospho-specific antibodies is commonly used to monitor autophosphorylation and downstream pathway activation. These methods are essential for confirming that a mutation or knockout alters kinase activity.
Structural and Biophysical Approaches
X-ray crystallography, cryo-EM, and NMR have provided detailed insights into RTK ectodomain-ligand interactions, transmembrane helix packing, and kinase domain conformations. These techniques help explain how mutations affect activation and how inhibitors bind.
Functional Screens and Animal Models
CRISPR library screens can identify synthetic lethal interactions and resistance mechanisms involving RTKs. Mouse models with conditional knockouts or knock-ins of RTK genes recapitulate human disease phenotypes and are valuable for preclinical drug testing.
How CRISPR Can Be Used to Study GO:0004714 transmembrane receptor protein tyrosine kinase activity
Knockout
CRISPR knockout of RTK genes is used to completely abolish receptor expression and assess its contribution to cellular phenotypes. For example, knocking out EGFR in lung cancer cell lines can reduce proliferation and downstream MAPK signaling. Knockout models are also valuable for validating drug targets and identifying compensatory pathways.
Point Mutation
Point-mutation knock-in allows precise introduction of clinically relevant mutations, such as EGFR L858R or KIT D816V, to study their impact on kinase activity, signaling, and drug sensitivity. These models are essential for understanding oncogenic mechanisms and for testing targeted therapies.
Knock-in
Knock-in of fusion genes or tagged receptors enables the study of oncogenic rearrangements and receptor dynamics. For instance, knock-in of EML4-ALK recapitulates the fusion found in lung cancer and allows evaluation of ALK inhibitors. Tagged knock-in (e.g., GFP or HA) facilitates imaging and proteomic analysis of the receptor.
Overexpression
Overexpression of wild-type or mutant RTKs mimics gene amplification observed in tumors and can drive transformation in vitro and in vivo. This approach is useful for studying dose-dependent signaling and for generating models of acquired resistance to kinase inhibitors.
How EDITGENE Supports transmembrane receptor protein tyrosine kinase activity Research
Researchers studying transmembrane receptor protein tyrosine kinase activity-related genes often need to determine whether a candidate gene is causally involved in a specific phenotype, how mutations alter kinase function, or whether a fusion drives oncogenesis. EDITGENE provides end-to-end CRISPR services to generate precisely engineered cell models that answer these questions.
Contact EDITGENE today to design your custom CRISPR model for transmembrane receptor protein tyrosine kinase activity research.
Frequently Asked Questions About transmembrane receptor protein tyrosine kinase activity
What is GO:0004714?
GO:0004714 is the Gene Ontology term for transmembrane receptor protein tyrosine kinase activity, a molecular function where a membrane receptor binds a signal and phosphorylates protein tyrosine residues using ATP.
What genes are involved in transmembrane receptor protein tyrosine kinase activity?
Key genes include EGFR, ERBB2, FGFR1, INSR, KIT, and many other receptor tyrosine kinases.
What is the function of receptor tyrosine kinases?
They transmit extracellular signals across the plasma membrane by phosphorylating tyrosine residues on target proteins, initiating signaling cascades that control proliferation, survival, and metabolism.
How are receptor tyrosine kinases activated?
Ligand binding induces receptor dimerization, which relieves autoinhibition and allows trans-autophosphorylation of the kinase domains.
What diseases are associated with RTK mutations?
Cancers such as lung, breast, and gastrointestinal tumors, as well as metabolic disorders like diabetes and skeletal disorders.
How can I study transmembrane receptor protein tyrosine kinase activity?
Common methods include CRISPR knockout, phospho-proteomics, Western blotting, structural biology, and animal models.
What is the reaction catalyzed by GO:0004714?
ATP + a protein-L-tyrosine = ADP + a protein-L-tyrosine phosphate.
Which RTK is targeted in gastrointestinal stromal tumors?
KIT is a primary target, with mutations such as D816V driving disease.
Can CRISPR be used to model RTK mutations?
Yes, CRISPR knock-in can introduce specific point mutations or fusions to model oncogenic RTK variants.
What are the challenges in targeting RTKs therapeutically?
Drug resistance often emerges through secondary mutations or bypass signaling, requiring combination therapies or next-generation inhibitors.
Conclusion
GO:0004714, transmembrane receptor protein tyrosine kinase activity, is a central molecular function that governs how cells interpret extracellular signals. Its dysregulation underlies many cancers and metabolic disorders, making it a prime target for therapeutic intervention. Understanding the mechanisms of RTK activation, regulation, and downstream signaling is essential for developing effective treatments. CRISPR-based models offer powerful tools to dissect these mechanisms and identify new drug targets. EDITGENE provides comprehensive CRISPR services to support research on RTKs, from knockout and point-mutation models to library screening and bioinformatics. By leveraging these tools, researchers can accelerate discoveries in RTK biology and translate them into clinical advances.
References
- 1. Roskoski R Jr. 2014. The ErbB/HER family of protein-tyrosine kinases and cancer.. Pharmacol Res 79:34-74 PMID: 24269963
- 2. Katoh M. 2016. FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review).. Int J Mol Med 38(1):3-15 PMID: 27245147
- 3. Trenker R et al.. 2020. Receptor tyrosine kinase activation: From the ligand perspective.. Curr Opin Cell Biol 63:174-185 PMID: 32114309
- 4. Rizzo S et al.. 2024. Identifying Transmembrane Interactions in Receptor Protein Tyrosine Phosphatase Homodimerization and Heterodimerization.. Methods Mol Biol 2743:195-209 PMID: 38147217
- 5. Hubbard SR et al.. 2000. Protein tyrosine kinase structure and function.. Annu Rev Biochem 69:373-98 PMID: 10966463
- 6. Roskoski R Jr. 2004. The ErbB/HER receptor protein-tyrosine kinases and cancer.. Biochem Biophys Res Commun 319(1):1-11 PMID: 15158434
- 7. Gammeltoft S et al.. 1986. Protein kinase activity of the insulin receptor.. Biochem J 235(1):1-11 PMID: 3017297
- 8. Roskoski R Jr. 2005. Structure and regulation of Kit protein-tyrosine kinase--the stem cell factor receptor.. Biochem Biophys Res Commun 338(3):1307-15 PMID: 16226710
